Clinical Trial Update: Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for LFX453 in actinic keratosis, reporting safety, tolerability, and efficacy with completed status and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• LFX453

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Actinic Keratosis | Phase 2 | Status: COMPLETED | Results posted: 2018-03-19